Abstract Number: 1180 • 2013 ACR/ARHP Annual Meeting
Rising Burden Of Gout and Poor Management Of The Disease In The United Kingdom: A Nationwide Population Study
Background/Purpose: To describe the trends of epidemiology of gout and patterns of urate-lowering treatment in the UK general population from 1997-2012. Methods: We used the…Abstract Number: 1181 • 2013 ACR/ARHP Annual Meeting
The Effect Of Uric Acid Lowering Therapy In Preventing Comorbidity and Acute Attack Of Gout; A Retrospective Study
Background/Purpose: We evaluated the effect of uric acid lowering therapy (ULT) in reducing the new development of comorbidities and the frequency of acute attacks…Abstract Number: 1182 • 2013 ACR/ARHP Annual Meeting
The Performance Of a Diagnostic Rule For Acute Gouty Arthritis Without Joint Fluid Analysis: a Validation Study
Background/Purpose: The gold standard to diagnose gout is the identification of monosodium urate (MSU) crystals in joint fluid. In primary care gout is mostly diagnosed…Abstract Number: 1183 • 2013 ACR/ARHP Annual Meeting
The Treatment Of Gout In Relation To The 2012 Uric Acid Target Guidelines In The US Population
The Treatment of Gout in Relation to the 2012 Uric Acid Target Guidelines in the US Population Background/Purpose: Gout is a debilitating form of arthritis mediated…Abstract Number: 1184 • 2013 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Plays a Role In Gouty Arthritis
Background/Purpose: High mobility group box 1 (HMGB1) is a crucial cytokine that mediated the response to infection, injury and inflammation. It is recently discovered that…Abstract Number: 1185 • 2013 ACR/ARHP Annual Meeting
More Than One-Third Of Patients Reach Serum Urate Target and Continue To Report Multiple Flares
Background/Purpose: Gout is a common inflammatory arthritis, and its worldwide prevalence is increasing. EULAR and ACR guidelines recommend a target serum urate (sUA) ≤6 mg/dL.…Abstract Number: 1186 • 2013 ACR/ARHP Annual Meeting
Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries
Background/Purpose: Allopurinol is the most commonly used urate-lowering therapy (ULT) in the world. Although allopurinol is FDA approved for up to 800 mg/d and EMEA…Abstract Number: 1187 • 2013 ACR/ARHP Annual Meeting
A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout
Background/Purpose: Documentation of the safety profile of allopurinol at doses ≥300 mg/day is important for its ongoing use as first-line monotherapy or in combination with…Abstract Number: 1188 • 2013 ACR/ARHP Annual Meeting
An Assessment Of The Response Of Chronic, Occult, Synovial-Based Inflammation Of Gout To Serum Urate Lowering Therapy
Background/Purpose: We recently demonstrated that synovitis is present in the vast majority of patients with inter-critical gout and that the severity of this synovitis did…Abstract Number: 1189 • 2013 ACR/ARHP Annual Meeting
Allopurinol Dose Titration and Efficacy: A Large-Scale, 6-Month, Multicenter, Prospective Study
Background/Purpose: Allopurinol is the first-line urate-lowering therapy (ULT) for most people with gout, but target serum uric acid (sUA) levels of 200-300 >300-400 >400-500 >500-600…Abstract Number: 1190 • 2013 ACR/ARHP Annual Meeting
The Synergistic Effects Of Metabolic Syndrome Indicators and Hyperuricemia In Contributing To Cardiac Event Risk: A Cross-Sectional Examination Of The Nhanes III Data
Background/Purpose: The focus of this project is to assess the contribution of hyperuricemia and gout to the risk for cardiovascular events. In a preliminary analysis…Abstract Number: 1191 • 2013 ACR/ARHP Annual Meeting
Low-Dose Anakinra Is Effective For The Prophylaxis Of Acute Episodes Of Inflammation In Severe Tophaceous Gout
Background/Purpose: anakinra has been used off-label for the treatment of severe episodes of acute inflammation (EAIs) in gout. Only a retrospective series of 3 patients…Abstract Number: 1192 • 2013 ACR/ARHP Annual Meeting
Pharmacovigilance Update On Pegloticase For Treatment Refractory Gout: United States Clinical Experience Demonstrates The Value Of Serum Uric Acid Monitoring As a Biomarker Of Risk and Efficacy
Background/Purpose: Pegloticase was approved in the US in late 2010 for patients with chronic gout refractory to xanthine oxidase inhibitors (XOIs). The clinical development program…Abstract Number: 1193 • 2013 ACR/ARHP Annual Meeting
Target Tophus Size and Complete Response Rates In Patients Treated With Open-Label Pegloticase For Chronic Gout Refractory To Conventional Therapy
Background/Purpose: Pegloticase, a methoxyPEG-conjugated mammalian recombinant uricase, has been approved in the US and EU for the treatment of chronic gout refractory to xanthine oxidase…Abstract Number: 1167 • 2013 ACR/ARHP Annual Meeting
A Possible Mechanism Of NLRP3 Inflammasome Hypersensitivity In Cryopyrin-Associated Periodic Syndrome
Background/Purpose: NLRP3 in monocytes and other cell types plays a role in innate immunity as one of the intracellular pathogen recognition receptors, and its mutation…